Chinese state media say that a COVID-19 vaccine developed by Sinopharm's China National Biotec Group (CNBG) is promising candidate for potential approval in China for use in children and adolescents before March, as reported in Fidelity.
CNBG chairman Yang Xiaoming remarked "based on clinical data we have obtained and regulatory procedures we are filing to National Medical Products Administration, [the vaccine use] could be expanded to these aged between three and 17 before March," although he did not elaborate on the data.
Children aged three to five, whose immune system is still developing, must be carefully and closely monitored during vaccination, Yang noted.
CNBG has two COVID-19 vaccines in Phase III trials, both of which have been authorised for emergency use and given to limited priority groups at high risk of infection.
It was not immediately clear which CNBG vaccine Yang was referring to in his comments about clinical trials on children and teenagers.
To read more NewsPoints articles, click here.